Welcome to our dedicated page for Icecure Medical Ltd. news (Ticker: ICCM), a resource for investors and traders seeking the latest updates and insights on Icecure Medical Ltd. stock.
IceCure Medical Ltd. (Nasdaq: ICCM) is a commercial-stage medical device company that develops liquid-nitrogen-based cryoablation systems for minimally invasive destruction of benign and cancerous tumors. News about IceCure often centers on its flagship ProSense® Cryoablation System and its role as an option to surgical tumor removal, particularly in breast cancer and other oncology indications.
Investors and clinicians following ICCM news can expect updates on regulatory milestones, commercial expansion, and clinical data. Recent company communications highlight U.S. Food and Drug Administration (FDA) marketing authorization for ProSense® for the local treatment of low-risk breast cancer with adjuvant endocrine therapy in women aged 70 and above, including those not suitable for surgery. News items also cover regulatory approvals in markets such as Switzerland and Israel, as well as patent developments for next-generation systems like XSense™ and cryogen flow control technologies.
IceCure’s news flow frequently includes coverage of independent clinical studies and conference presentations. ProSense® has been featured in abstracts and talks at major meetings such as the Radiological Society of North America (RSNA) Annual Meeting, the Cardiovascular and Interventional Radiology Society of Europe (CIRSE) Annual Meeting, and the European Society of Breast Imaging (EUSOBI) Congress. These reports describe clinical experience in breast cancer, lung cancer, musculoskeletal tumors, kidney lesions, and abdominal wall endometriosis.
Company updates may also address financial and operational results, commercial traction in regions including North America and Europe, and interactions with Nasdaq listing requirements. For users tracking ICCM, this news page provides a centralized view of press releases, clinical milestones, regulatory developments, and commercialization updates related to IceCure’s cryoablation platforms.
Apartment Investment and Management Company (NYSE: AIV) disclosed the federal tax character of its 2025 distributions to Class A common stockholders. Aimco reported total 2025 distributions of $2.83 per share, which the company allocated as 100.00% total capital gain and 0.00% ordinary dividends. The company disclosed an unrecaptured Sec. 1250 gain of ~33.7355% and Section 897 capital gain 100.00% for the distributions. Aimco noted its 2025 tax return has not yet been filed and the allocation is based on the best available information. Aimco also referenced its announced Plan of Sale and Liquidation and a Definitive Proxy Statement filed January 2, 2026, in connection with a forthcoming stockholder vote.
IceCure (Nasdaq: ICCM) reported record 2025 ProSense® sales of approximately $3.4 million and cash and cash equivalents of approximately $8.9 million as of December 31, 2025, based on preliminary unaudited estimates. In October 2025 the company received FDA marketing authorization for ProSense® for local treatment of low-risk breast cancer in women aged 70+ with endocrine therapy, making it the first and only device with that FDA authorization. The company reported record European sales, expanded scientific publications and presentations, four new U.S. and China patents, and reimbursement under CPT III at $4,049 effective January 2026.
IceCure (NASDAQ: ICCM) expects record fourth quarter North American sales driven by increased orders and installations of its ProSense® cryoablation system following the FDA marketing authorization in October 2025 for local treatment of low-risk breast cancer in women aged 70 and above. The company reports rapid interest from hospitals, breast surgeons and radiologists, including orders from a highly ranked U.S. hospital network, and says ProSense® is receiving broad media and conference visibility. IceCure plans preliminary top-line revenue disclosure in January 2026 and its full Form 20-F in April 2026.
IceCure (NASDAQ: ICCM) reported that four independent abstracts featuring its ProSense cryoablation system were presented at RSNA 2025 (Nov 30–Dec 4, 2025).
Key data from three studies covering 263 patients include: 100% success for luminal cancers ≤2.5 cm, complete necrosis 81.2% in a 73‑patient cohort, Cryoablation+HT tumor reduction 83.3% (mean 13.6 mm) versus HT‑only 42.1%, and CEM showing NPV and sensitivity 100% for cryoablation assessment. The company noted growing adoption following the FDA marketing approval for low‑risk breast cancer.
IceCure Medical (Nasdaq: ICCM) presented ProSense® liquid-nitrogen single‑probe cryoablation data and training at CIRSE 2025 in Barcelona, highlighting independent clinical studies and hands‑on sessions for interventional radiologists.
Key items: PRECICE will treat 234 Luminal A/B patients >50; a prospective series reported outcomes for 55 elderly HR+/HER2- patients (median age 86); a cohort of 39 inoperable malignant lesions showed efficacy in small, low‑grade HR+ unifocal IDC; an AWE study reported pain scores falling from 8 to 1 and MRI necrosis/resolution in 95% of cases.
IceCure (NASDAQ: ICCM) received a Notice of Allowance in China for a patent titled "Cryogen Flow Control" on Dec 5, 2025, covering temperature regulation for its next-generation XSense cryoablation system and probes.
The invention builds on prior intellectual property wins, with the same patent granted in Japan and pending in the EU, U.S., and other markets, and contributes to IceCure's stated 55 patents granted and allowed globally. The technology aims to use sensor-driven flow control to maintain distal tip temperatures, improve efficacy and tissue safety, and support navigation/mapping features. IceCure notes its ProSense cryoablation system has FDA marketing authorization for local treatment of low-risk breast cancer in specified patients.
IceCure (NASDAQ: ICCM) reported results for the nine months ended September 30, 2025 and highlighted a landmark FDA marketing authorization (Oct 2025) for ProSense® for low-risk breast cancer in patients ≥70 with tumors ≤1.5 cm.
Key operational notes: planned commercial rollout to 30 U.S. sites with a ~400-patient post-market study, Switzerland regulatory clearance, reimbursement under CPT III (facility portion ~$3,800, rising to >$4,000 Jan 2026), and patent notices for XSense™ in U.S./Japan.
Financials: nine-month revenue of $2.1M, gross margin 30%, net loss $10.8M, and cash of approximately $10.0M as of Sept 30, 2025.
IceCure (NASDAQ: ICCM) announced that Swissmedic approved its ProSense® cryoablation system and cryoprobes for treating malignant or benign tissue of the breast, lung, liver, kidney and musculoskeletal (bone), including palliative interventions. The approval, announced November 18, 2025, matches ProSense® indications already approved in the European Union.
The company said this Swiss registration complements recent U.S. FDA marketing authorization for ProSense® in low-risk breast cancer and supports IceCure's commercial expansion in Europe. The release notes Switzerland's large healthcare market, citing a KOF estimate of a $120 billion healthcare market in 2023 and healthcare spending near 12% of GDP.
IceCure Medical (Nasdaq: ICCM) received a Nasdaq written notice on Nov 14, 2025 for noncompliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).
Nasdaq granted a 180-calendar-day cure period ending May 11, 2026. The company can regain compliance if its closing bid is at least $1.00 for 10 consecutive business days. The notice does not affect current listing or trading during the cure period. If compliance is not regained, the company may request a second 180-day period only if it meets market value of publicly held shares and other listing standards (except the minimum bid), but failure to cure can lead to Nasdaq delisting.
IceCure Medical (Nasdaq: ICCM) will report its financial and operating results for the nine months ended September 30, 2025 on Wednesday, November 19, 2025 before the Nasdaq opens.
The company will host a conference call and webcast to discuss results and corporate developments at 10:00 a.m. EST the same day. Dial-in numbers are provided for US and Israel/international participants, and a live webcast plus a recording will be available via the company links.
FAQ
What is the current stock price of Icecure Medical Ltd. (ICCM)?
What is the market cap of Icecure Medical Ltd. (ICCM)?
